Enhabit, Inc. (NYSE:EHAB) Given Consensus Rating of “Hold” by Brokerages

Shares of Enhabit, Inc. (NYSE:EHAB) have earned an average recommendation of “Hold” from the six ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $8.75.

Several equities research analysts have recently issued reports on the stock. Leerink Partners reaffirmed a “market perform” rating and set a $8.00 price objective (down from $8.50) on shares of Enhabit in a research report on Tuesday, November 19th. Jefferies Financial Group raised shares of Enhabit from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $8.25 to $9.50 in a research report on Monday, December 9th.

Insider Activity at Enhabit

In other Enhabit news, Director Stuart M. Mcguigan acquired 15,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were bought at an average cost of $8.81 per share, for a total transaction of $132,150.00. Following the completion of the purchase, the director now owns 46,810 shares in the company, valued at $412,396.10. This trade represents a 47.15 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey Bolton acquired 4,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $8.69 per share, for a total transaction of $34,760.00. Following the completion of the purchase, the director now owns 98,144 shares of the company’s stock, valued at $852,871.36. This trade represents a 4.25 % increase in their position. The disclosure for this purchase can be found here. 1.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Franklin Resources Inc. increased its stake in shares of Enhabit by 19.6% during the third quarter. Franklin Resources Inc. now owns 32,382 shares of the company’s stock worth $256,000 after acquiring an additional 5,317 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Enhabit by 37.8% during the third quarter. JPMorgan Chase & Co. now owns 305,245 shares of the company’s stock worth $2,411,000 after acquiring an additional 83,707 shares during the period. Paradice Investment Management LLC increased its stake in shares of Enhabit by 12.8% during the fourth quarter. Paradice Investment Management LLC now owns 1,780,113 shares of the company’s stock worth $13,903,000 after acquiring an additional 201,997 shares during the period. Systematic Financial Management LP increased its stake in shares of Enhabit by 12.2% during the third quarter. Systematic Financial Management LP now owns 1,838,199 shares of the company’s stock worth $14,522,000 after acquiring an additional 199,235 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Enhabit during the third quarter worth about $215,000.

Enhabit Price Performance

Enhabit stock opened at $8.55 on Thursday. The stock has a market cap of $430.13 million, a P/E ratio of -3.69 and a beta of 1.83. The company has a fifty day simple moving average of $8.16 and a 200-day simple moving average of $7.90. Enhabit has a 12-month low of $6.85 and a 12-month high of $11.74. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.